Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A, Iacobucci I, Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, Martinelli G. Ghelli Luserna Di Rorà A, et al. Among authors: derenzini e. Oncotarget. 2016 Aug 16;7(33):53377-53391. doi: 10.18632/oncotarget.10535. Oncotarget. 2016. PMID: 27438145 Free PMC article.
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
Mazzara S, Travaini L, Botta F, Granata C, Motta G, Melle F, Fiori S, Tabanelli V, Vanazzi A, Ramadan S, Radice T, Raimondi S, Lo Presti G, Ferrari ME, Jereczek-Fossa BA, Tarella C, Ceci F, Pileri S, Derenzini E. Mazzara S, et al. Among authors: derenzini e. Blood Adv. 2023 Feb 28;7(4):630-643. doi: 10.1182/bloodadvances.2022007825. Blood Adv. 2023. PMID: 36806558 Free PMC article.
Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series.
Maraglino AME, Amato V, Sammassimo S, Gigli F, Tabanelli V, Pastano R, Tarella C, Giglio F, Derenzini E. Maraglino AME, et al. Among authors: derenzini e. Leuk Lymphoma. 2023 Oct;64(10):1719-1722. doi: 10.1080/10428194.2023.2234524. Epub 2023 Jul 14. Leuk Lymphoma. 2023. PMID: 37450318 No abstract available.
[18 F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma.
Travaini LL, Botta F, Derenzini E, Lo Presti G, Ferrari ME, Airò Farulla LS, Radice T, Mazzara S, Tarella C, Pileri S, Raimondi S, Ceci F. Travaini LL, et al. Among authors: derenzini e. Hematol Oncol. 2023 Oct;41(4):674-682. doi: 10.1002/hon.3171. Epub 2023 May 20. Hematol Oncol. 2023. PMID: 37209024 Free article.
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G. Iacobucci I, et al. Among authors: derenzini e. J Hematol Oncol. 2015 Nov 5;8:125. doi: 10.1186/s13045-015-0206-5. J Hematol Oncol. 2015. PMID: 26542114 Free PMC article.
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
Trino S, Iacobucci I, Erriquez D, Laurenzana I, De Luca L, Ferrari A, Ghelli Luserna Di Rorà A, Papayannidis C, Derenzini E, Simonetti G, Lonetti A, Venturi C, Cattina F, Ottaviani E, Abbenante MC, Russo D, Perini G, Musto P, Martinelli G. Trino S, et al. Among authors: derenzini e. Oncotarget. 2016 Mar 15;7(11):12951-61. doi: 10.18632/oncotarget.7339. Oncotarget. 2016. PMID: 26887044 Free PMC article.
98 results